Evaluation of the probiotic properties of new Lactobacillus and Bifidobacterium strains and their in vitro effect.
Probiotic ingestion is recommended as a preventive approach to maintain the balance of the intestinal microbiota and to enhance the human well-being. During the whole life of each individual, the gut microbiota composition could be altered by lifestyle, diet, antibiotic therapies and other stress conditions, which may lead to acute and chronic disorders. Hence, probiotics can be administered for the prevention or treatment of some disorders, including lactose malabsorption, acute diarrhoea, irritable bowel syndrome, necrotizing enterocolitis and mild forms of inflammatory bowel disease. The probiotic-mediated effect is an important issue that needs to be addressed in relation to strain-specific probiotic properties. In this work, the probiotic properties of new Lactobacillus and Bifidobacterium strains were screened, and their effects in vitro were evaluated. They were screened for probiotic properties by determining their tolerance to low pH and to bile salts, antibiotic sensitivity, antimicrobial activity and vitamin B8, B9 and B12 production, and by considering their ability to increase the antioxidant potential and to modulate the inflammatory status of systemic-miming cell lines in vitro. Three out of the examined strains presenting the most performant probiotic properties, as Lactobacillus plantarum PBS067, Lactobacillus rhamnosus PBS070 and Bifidobacterium animalis subsp. lactis PBSO75, were evaluated for their effects also on human intestinal HT-29 cell line. The obtained results support the possibility to move to another level of study, that is, the oral administration of these probiotical strains to patients with acute and chronic gut disorders, by in vivo experiments.
Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy.
I
I
Presti
G
G
D'Orazio
M
M
Labra
B
B
La Ferla
V
V
Mezzasalma
G
G
Bizzaro
S
S
Giardina
A
A
Michelotti
F
F
Tursi
M
M
Vassallo
P
P
Di Gennaro
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000898:Antibiosis; D000975:Antioxidants / Q000378:metabolism; D001644:Bifidobacterium / Q000187:drug effects / Q000276:immunology / Q000302:isolation & purification / Q000502:physiology*; D001647:Bile Acids and Salts / Q000378:metabolism; D002460:Cell Line; D004269:DNA, Bacterial / Q000737:chemistry / Q000235:genetics; D004275:DNA, Ribosomal / Q000737:chemistry / Q000235:genetics; D004847:Epithelial Cells / Q000382:microbiology / Q000502:physiology; D005347:Fibroblasts / Q000382:microbiology / Q000502:physiology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007778:Lactobacillus / Q000187:drug effects / Q000276:immunology / Q000302:isolation & purification / Q000502:physiology*; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D019936:Probiotics; D012336:RNA, Ribosomal, 16S / Q000235:genetics; D017422:Sequence Analysis, DNA; D014803:Vitamin B Complex / Q000378:metabolism
D000900:Anti-Bacterial Agents; D000975:Antioxidants; D001647:Bile Acids and Salts; D004269:DNA, Bacterial; D004275:DNA, Ribosomal; D012336:RNA, Ribosomal, 16S; D014803:Vitamin B Complex